OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
KLKIM58

Kalekim Kimyevi Maddeler Sanayi ve Ticaret AS

Commodity ChemicalsVerified

Kalekim maintains a strong liquidity position with a current ratio of 2.15, indicating the company can cover its short-term liabilities more than twice over. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. The company's debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal reliance on debt financing. Profitability metrics show that Kalekim is performing well relative to industry norms. The company's return on equity (ROE) is 17.47%, and return on assets (ROA) is 11.51%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that Kalekim is generating solid returns for its shareholders and effectively utilizing its asset base. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is based in Turkey, and its exposure is primarily to the domestic market. This concentration may increase vulnerability to local economic conditions and regulatory changes. Kalekim's growth trajectory appears stable, with no specific revenue growth rates provided in the data. Analysts have assigned a mean price target of 48.73 TRY, with a median of 48.60 TRY, suggesting a generally positive outlook. The company's operating cash flow of 1.27 billion TRY and free cash flow of 472.4 million TRY support its ability to fund operations and invest in future growth. The company faces moderate liquidity risk due to its negative net cash position after accounting for total debt. While the risk of dilution is currently low, the company's capital expenditure of -834.1 million TRY indicates a significant outlay, which could affect future earnings if not offset by revenue growth. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.

30-day price · KLKIM-4.78 (-13.2%)
Low$29.84High$37.91Close$31.56As of25 May, 00:00 UTC
Profile
CompanyKalekim Kimyevi Maddeler Sanayi ve Ticaret AS
TickerKLKIM.IS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Kalekim Kimyevi Maddeler Sanayi ve Ticaret AS produces and distributes chemical products, primarily serving industrial and manufacturing sectors.

Classification. Kalekim is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Kalekim maintains a strong liquidity position with a current ratio of 2.15, indicating the company can cover its short-term liabilities more than twice over. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. The company's debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal reliance on debt financing. Profitability metrics show that Kalekim is performing well relative to industry norms. The company's return on equity (ROE) is 17.47%, and return on assets (ROA) is 11.51%, both of which are strong indicators of efficient capital use and asset management. These figures suggest that Kalekim is generating solid returns for its shareholders and effectively utilizing its asset base. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is based in Turkey, and its exposure is primarily to the domestic market. This concentration may increase vulnerability to local economic conditions and regulatory changes. Kalekim's growth trajectory appears stable, with no specific revenue growth rates provided in the data. Analysts have assigned a mean price target of 48.73 TRY, with a median of 48.60 TRY, suggesting a generally positive outlook. The company's operating cash flow of 1.27 billion TRY and free cash flow of 472.4 million TRY support its ability to fund operations and invest in future growth. The company faces moderate liquidity risk due to its negative net cash position after accounting for total debt. While the risk of dilution is currently low, the company's capital expenditure of -834.1 million TRY indicates a significant outlay, which could affect future earnings if not offset by revenue growth. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.
Key takeaways
  • Kalekim has a strong liquidity position with a current ratio of 2.15.
  • The company's ROE of 17.47% and ROA of 11.51% indicate efficient capital and asset use.
  • The company's revenue is concentrated in a single segment and geographic market.
  • Analysts have a generally positive outlook, with a mean price target of 48.73 TRY.
  • The company faces moderate liquidity risk due to a negative net cash position after debt.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTRY
Revenue$10.70B
Gross profit$4.38B
Operating income$2.06B
Net income$1.14B
R&D
SG&A
D&A
SBC
Operating cash flow$1.27B
CapEx-$834.1M
Free cash flow$472.4M
Total assets$9.87B
Total liabilities$3.37B
Total equity$6.50B
Cash & equivalents$172.2M
Long-term debt$369.7M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.50B
Net cash-$197.5M
Current ratio2.1
Debt/Equity0.1
ROA11.5%
ROE17.5%
Cash conversion1.1%
CapEx/Revenue-7.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricKLKIMActivity
Op margin19.2%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin10.6%4.1% medp25 0.1% · p75 8.8%top quartile
Gross margin41.0%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-7.8%-6.2% medp25 -13.4% · p75 -2.6%below median
Debt / equity6.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Observations
IR observations
Mean price target48.73 TRY
Median price target48.60 TRY
High price target50.18 TRY
Low price target47.40 TRY
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate3.00 TRY
Mean revenue estimate11,567,000,000 TRY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 01:47 UTC#864bf47f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 08:17 UTCJob: 541d52f9